|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,945.00 INR | -0.31% |
|
-2.29% | +13.10% |
| 08-05 | CRISIL Keeps AAA Rating on Sun Pharmaceutical's Bank Facilities | MT |
| 07-31 | Sun Pharmaceutical Industries Limited, Q1 2027 Earnings Call, Jul 31, 2026 |
| Market Cap | 4,667B 49.03B 42.41B 39.61B 36.34B 68.34B 69.43B 465B 182B 2,339B 184B 180B 7,733B | P/E 2027 * |
35.8x | P/E 2028 * | 30.2x |
|---|---|---|---|---|---|
| Enterprise Value | 4,388B 46.1B 39.88B 37.24B 34.16B 64.26B 65.28B 437B 171B 2,199B 173B 169B 7,270B | EV / Sales 2027 * |
6.74x | EV / Sales 2028 * | 5.92x |
| Free-Float |
44.39% | Yield 2027 * |
0.88% | Yield 2028 * | 1.02% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | -0.31% | ||
| 1 week | -2.29% | ||
| Current month | -2.29% | ||
| 1 month | +3.01% | ||
| 3 months | +5.25% | ||
| 6 months | +14.74% | ||
| Current year | +13.10% |
| 1 week | 1,925.1 |  | 1,988 |
| 1 month | 1,910 | | 2,046.9 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,548 | | 2,046.9 |
| 3 years | 1,068.35 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.31% | -2.29% | +22.57% | +69.33% | 49.03B | |
| +4.40% | +14.46% | +62.66% | +133.25% | 42.33B | |
| -0.89% | -0.64% | -1.48% | +15.58% | 12.43B | |
| +0.56% | -1.12% | +19.02% | +70.02% | 11.68B | |
| +0.19% | +0.77% | +31.74% | +141.01% | 9.12B | |
| +1.99% | +4.41% | +17.56% | +34.79% | 7.15B | |
| +1.82% | -0.15% | +39.41% | -13.77% | 7.09B | |
| +0.40% | +2.02% | +12.85% | +176.30% | 6.76B | |
| +6.44% | +8.26% | -24.61% | +30.64% | 5.95B | |
| +0.54% | +0.69% | +33.92% | +99.35% | 4.58B | |
| Average | +1.51% | +2.53% | +21.36% | +75.65% | 15.61B | |
| Weighted average by Cap. | +1.53% | +3.66% | +30.44% | +85.30% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 651B 6.84B 5.92B 5.53B 5.07B 9.54B 9.69B 64.84B 25.45B 326B 25.69B 25.13B 1,079B | 730B 7.67B 6.63B 6.19B 5.68B 10.68B 10.85B 72.65B 28.51B 366B 28.79B 28.16B 1,209B |
| Net income | 130B 1.37B 1.19B 1.11B 1.02B 1.91B 1.94B 12.99B 5.1B 65.4B 5.15B 5.04B 216B | 155B 1.63B 1.41B 1.32B 1.21B 2.27B 2.31B 15.44B 6.06B 77.71B 6.12B 5.98B 257B |
| Net Debt | -279B -2.93B -2.54B -2.37B -2.17B -4.09B -4.15B -27.79B -10.91B -140B -11.01B -10.77B -462B | -349B -3.67B -3.17B -2.96B -2.72B -5.11B -5.19B -34.77B -13.65B -175B -13.78B -13.48B -579B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 07/08/26 | ₹1,945.00 | -0.31% | 2,425,268 |
| 06/08/26 | ₹1,951.00 | +0.57% | 1,864,891 |
| 05/08/26 | ₹1,940.00 | -1.22% | 2,152,829 |
| 04/08/26 | ₹1,964.00 | +0.03% | 1,452,888 |
| 03/08/26 | ₹1,963.50 | -1.36% | 3,972,351 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
